When AI saves lives: iCAD's FDA-cleared imaging solution & the Future of Healthcare

Listen to Codrin Arsene interview Michael Klein, the CEO @ iCAD,
one of the few FDA-approved artificial intelligence solutions for
radiologists. iCAD's AI analyzes hundreds of data-points to deliver
powerful software solutions for breast tomosynthesis, breast
density and 2D mammography. In simple terms, the iCAD software
(Profound AI) analyzes mammogram images and correlates them to
demographic data to produce cancer probability scores for
radiologists. Whereas iCAD cannot officially 'diagnose' breast
cancer, the software alerts radiologists of any abnormalities tied
to mammogram images for further inspection. In the clinical trial
which led to iCAD getting FDA approval, Profound AI was responsible
for detecting 8% more cancers than the group of radiologists that
analyzed the same data set. Listen to the podcast to learn about
the history of iCAD, their current AI solution, new exciting
features and functionalities iCAD plans to release later this year
and the future of AI in healthcare.